Endocyte Inc (ECYT): Philip S Low , Chief Science Officer of Endocyte Inc purchased 11,375 shares on May 10, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.52 per share for a total value of $40,040.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 20, 2016, Fred A Middleton (director) purchased 30,000 shares at $2.80 per share price.On Mar 5, 2015, Binh Nguyen (VP of Medical Affairs) sold 29,883 shares at $5.79 per share price.
Endocyte: On Tuesday, May 10, 2016 heightened volatility was witnessed in Endocyte which led to swings in the share price. The shares opened for trading at $3.53 and hit $3.641 on the upside , eventually ending the session at $3.51, with a gain of 1.15% or 0.04 points. The heightened volatility saw the trading volume jump to 1,19,388 shares. The 52-week high of the share price is $6.35 and the company has a market cap of $148 M . The 52-week low of the share price is at $2.65.
Company has been under the radar of several Street Analysts.Endocyte is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 8 from a previous price target of $12 . The Rating was issued on Mar 3, 2016.
Endocyte Inc. (Endocyte) is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The Company’s pipeline includes: Vintafolide (Vynfinit or EC145) which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells but not on most normal cells; Folate-Tubulysin (EC1456) an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent tubulysin B hydrazide (TubBH); EC0652 a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169 an investigational injectable PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20) a folate-targeted molecular imaging agent; EC1669 a new approach to inflammation therapy targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371 a folate-targeted water-soluble form of rapamycin and EC1788 a Folate-targeted SMDC.